Clinical Trial Update: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating trastuzumab deruxtecan, alone or in combination with anastrozole, for early-stage HER2-low, hormone receptor–positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Status: RECRUITING